WATCH: recovery not established
Q2 better sequentially, H1 earnings depressed
Watch: Require recurring cash
Home / Research / Cohance Lifesciences Limited
WATCH: recovery not established
Issuer Q2 statutory results / presentation / analyst calculation
Issuer Q2 statutory results / presentation / analyst calculation
Issuer Q2 statutory results / presentation / analyst calculation
Issuer Q2 statutory results / presentation / analyst calculation
Q2 better sequentially, H1 earnings depressed
Watch: Require recurring cash
Still down 14.2% YoY
Watch: Track H2 deliveries
H2 recovery needed
Watch: Compare cumulative sales
Rounded management mix
Watch: Track business contribution
SAGE PRO Institutional Research | 16 November 2026 | Q2 FY2027 | NSE: COHANCE
Key takeaways
Q2 consolidated operating revenue was ₹476.65 crore, up 12.9% QoQ but down 14.2% YoY. Management reported EBITDA ₹35.5 crore versus ₹1.2 crore in Q1; adjusted EBITDA ₹45.9 crore (9.6% margin), versus ₹9.2 crore (2.2%).
H1 revenue declined 18.6% and reported EBITDA fell 84%. The critical accounting insight is that parent-attributable Q2 PAT ₹15.22 crore is not group operating profit: group PBT was negative ₹10.75 crore, a net tax benefit produced group PAT of ₹2.27 crore, and losses allocated to minorities of ₹12.95 crore raised parent profit.
An annualised Q2 P/E would misrepresent recurring economics.
At ₹457.60 (Sage PRO financial data, 16 November 2026, ~16:30 IST), September 38.26 crore shares imply ₹17,508 crore equity value and FY26 parent PAT ₹179.23 crore implies 97.7x. H1 loss makes run-rate P/E unhelpful. WATCH over 12–24 months.
Variant thesis: commercial reloads, Sapala and ADC integration can restore absorption; destocking, safety/regulatory issues and underutilised assets may delay returns. H2 growth is the immediate test. Source-verified longform; full QA open.
Cohance's Pharma CDMO develops and manufactures innovator molecules. Scientific contribution can include route optimisation, scale-up, impurity control and validation. Process continuity and customer qualification can support repeat business, but the customer controls product development, launch, supplier allocation and end-market demand. Commercial orders can be lumpy because clients change inventories and shipment timing. Management reported better Q3/Q4 small-molecule reloads, two new commercial lateral programmes and one Phase III award, with 19 commercial and 11 Phase III programmes. Cohance standalone commercial revenue was approximately 78%, not the group's commercial sales share. Count awards as progress, not as a disclosed revenue backlog. Track repeat batches, aggregate programme revenue and actual technology transfer.
Key takeaways
Niche technologies were 13.7% of Q2 sales, not all Sapala. Linker/payload and bioconjugation integration may expand client work, but require qualified repeat orders. Compare with Anthem/Sai integrated research-manufacturing and Neuland CMS/API using operating margin, cash and incremental returns, not an unverified sector multiple.
API+ combines established API and formulations businesses. Q2 sales rose 6.2% YoY with selective pricing; lower API volume, shipment phasing and raw-material inflation pressured margins. API+ accounted for 56% of rounded Q2 group mix; Pharma CDMO 35%, specialty chemicals 9%. At ₹476.65 crore group sales, implied contributions are about ₹267/167/43 crore, not separately audited statutory segments. Pharma CDMO declined 27.4% YoY and specialty chemicals 40.6%; the latter reflects agrochemical volume, pricing and phasing, while performance materials were relatively stable. Group CDMO share of 44% includes specialty chemicals, so avoid interpreting the full 44% as pharmaceutical CDMO. Ind AS 108 statutory reporting is one operating segment. Separate growth, mix and margin by management activity where disclosed; do not fabricate segment operating profits.
Key takeaways
| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 | H1 FY27 | H1 FY26 | FY26 |
|---|---|---|---|---|---|---|
| Operating revenue | 476.65 | 422.26 | 555.57 | 898.91 | 1104.88 | 2268.55 |
| Other income | 12.41 | 12.25 | 15.60 | 24.66 | 29.77 | 34.09 |
| Materials + inventory changes | 139.09 | 120.28 | 141.13 | 259.37 | 289.27 | 662.63 |
| Employee expense | 153.54 | 132.96 | 126.72 | 286.50 | 260.04 | 507.71 |
| Other expense | 148.64 | 167.86 | 166.77 | 316.50 | 322.61 | 671.22 |
| Derived operating EBITDA | 35.38 | 1.16 | 120.95 | 36.54 | 232.96 | 426.99 |
| D&A | 50.17 | 49.54 | 44.02 | 99.71 | 89.16 | 187.33 |
| Finance expense | 8.37 | 6.74 | 8.76 | 15.11 | 18.94 | 37.24 |
| PBT pre exception | -10.75 | -42.87 | 83.77 | -53.62 | 154.63 | 236.51 |
| Exceptional charge | 0 | 0 | 0 | 0 | 8.10 | 29.47 |
| Group PAT | 2.27 | -45.19 | 66.39 | -42.92 | 112.79 | 150.12 |
| Parent PAT | 15.22 | -24.12 | 74.08 | -8.90 | 122.96 | 179.23 |
| Basic EPS ₹ | 0.40 | -0.63 | 1.94 | -0.23 | 3.22 | 4.69 |
Operating EBITDA is revenue less materials/inventory, employee and other expenses, excluding other income. Q2 ₹35.38 + ₹12.41 other income − ₹50.17 D&A − ₹8.37 finance = negative ₹10.75 crore PBT. The presentation reports EBITDA ₹35.5 crore, Q2 FY26 ₹122.6 crore and H1 ₹36.7 crore vs ₹234.8 crore.
Differences reflect issuer classifications/rounding; the statutory-derived series is used consistently rather than forcing equality. Management's adjusted EBITDA adds ₹3.6 crore FX mark-to-market adjustment and ₹6.8 crore one-time items, reaching ₹45.9 crore.
Q1 adjusted ₹9.2 crore; H1 ₹55.1 crore versus prior H1 ₹262.9 crore. Merger and ESOP adjustments may help comparison, but recurring integration and stock-compensation costs are real owner economics.
Q2 sales rose ₹54.39 crore sequentially. Materials and inventory costs increased ₹18.81 crore, staff ₹20.58 crore, other expense declined ₹19.22 crore. Derived EBITDA improved ₹34.22 crore, an incremental margin about 63% from a weak base, not a permanent forward margin. YoY sales fell ₹78.92 crore; employee expenses rose ₹26.82 crore; materials/inventory fell ₹2.04 crore, other expense fell ₹18.13 crore. Operating EBITDA declined ₹85.57 crore. This is operating deleverage: scientific, manufacturing and integration resources did not shrink proportionately to revenue. Q2 recovery is encouraging but margin remains well below prior year. Material margin 70.8% vs 74.6% reflects mix, raw-material inflation and weaker commercial contribution. Statutory inventory change was a ₹97.55 crore credit vs ₹50.47 crore prior year. Combined cost and cash inventory movement are more informative than treating accounting inventory credits as permanent cash savings.
Q2 net tax benefit ₹13.02 crore includes ₹13.82 crore prior-year current tax credit, current tax ₹1.43 crore and deferred tax benefit ₹0.63 crore. Group PAT ₹2.27 crore, NCI loss ₹12.95 crore, parent PAT ₹15.22 crore. Removing the prior-year credit alone yields group loss ₹11.55 crore, an arithmetic sensitivity rather than audited adjusted profit. H1 group loss ₹42.92 crore, NCI loss ₹34.02 crore and parent loss ₹8.90 crore. FY26 group PAT ₹150.12 crore vs parent ₹179.23 crore. When subsidiaries become profitable, positive minority shares reduce parent earnings. Forecast attributable profit on normal tax and explicit minority assumptions, not recurring tax credits or NCI losses. Q2 adjusted PAT ₹7.4 crore as presented is not the same measure as group or parent statutory PAT.
FY26 operating revenue ₹2,268.55 crore less H1 FY26 ₹1,104.88 crore implies H2 ₹1,163.67 crore. H1 FY27 ₹898.91 crore. Flat FY27 revenue requires H2 ₹1,369.64 crore, +17.7% YoY and +52.4% vs H1. A 5% FY27 decline requires H2 ₹1,256.21 crore, +8.0% YoY. Repeating Q2 twice yields FY27 ₹1,852.21 crore, -18.4%. Management's positive H2 YoY outlook requires average quarterly sales above ₹581.84 crore, 22% above Q2, but does not necessarily imply flat annual sales. FY26 H2 derived EBITDA ₹194.03 crore; exceeding that at ₹1,163.67 crore sales requires >16.7% margin. This statutory hurdle differs from management's adjusted-EBITDA guidance; compare both on consistent definitions.
Key takeaways
The positive cash flow is not proof of sustainable earnings recovery. Receivable release from a high opening balance and tax refunds cannot be extrapolated indefinitely.
| H1 cash flow ₹cr | FY27 | FY26 |
|---|---|---|
| Pre-working-capital operating profit | 39.20 | 239.42 |
| Inventory movement | -172.03 | -125.51 |
| Receivables release | 230.59 | 205.58 |
| Payables/other liabilities | 73.55 | 2.92 |
| Cash generated before tax | 171.31 | 322.41 |
| Net tax cash flow | 16.75 | -61.27 |
| CFO | 188.06 | 261.14 |
| Physical capital purchases | 108.01 | 89.71 |
| CFO less capital purchases | 80.05 | 171.43 |
The cash proxy after physical capex declined about 53%; excludes financing, acquisition expenditure and sale proceeds. Management's Q2 free cash flow ₹133.8 crore uses a different period/definition, and H1 capex deployed ₹107.7 crore is close to statutory ₹108.01 crore purchases; do not subtract both.
H1 cash statement also records ₹44.96 crore subsidiary investment net of acquired cash, and ₹124.40 crore acquisition of additional subsidiary interest in financing. Deducting both from the simple ₹80.05 crore cash proxy gives negative ₹89.31 crore before other financing/investments.
This is an illustrative deployment bridge, not audited FCFE. Cash increased to ₹98.63 crore from ₹49.14 crore due also to investment and financing movements. A positive cash balance is not a substitute for recurring operating cash.
September inventory ₹734.34 crore vs March ₹562.23; receivables ₹469.02 vs ₹681.01; trade payables ₹364.32 vs ₹284.58. Narrow trade working capital fell from ₹958.66 to ₹839.04 crore, but inventory increased 30.6%. Receivables are roughly 95 days of annualised H1 sales, an ending-balance proxy, not contractual DSO. Inventory exceeds 40% of annualised H1 sales. Track ageing, customer-linked batches, shipment conversion and payment terms. Inventory can support stronger future deliveries or tie up capital if demand slips. Payable extensions and receivable collection may not repeat. Current assets ₹1,716.73 crore/current liabilities ₹865.39 crore imply 1.98x current ratio vs 2.78x in March; this is not cash coverage.
September borrowings ₹227.70 crore vs ₹169.67 crore March; leases ₹220.71 crore. Cash ₹98.63 crore, current investments ₹185.12 crore and other bank balances ₹9.18 crore approximate management cash-on-books ₹294.3 crore. Goodwill ₹1,290.19 crore is 22.7% of assets ₹5,680.18 crore; CWIP ₹215.81 crore. Acquisition returns and impairment matter.
The statutory note records additional 65% Aaruka Bio stake for ₹47.89 crore, ownership 90%, control from 19 September. Accounted for as asset acquisition under Ind AS 103, not business combination. Do not assume full-quarter recurring acquired revenue. Additional 11.3% NJ Bio interest cost ₹124.40 crore, raising ownership to 67.3%; related put-option liability and NCI derecognised. Increased ownership changes attributable earnings and cash exposure even at unchanged group operating profit. Compare acquisition economics using full invested capital, goodwill, lease obligations and actual subsidiary cash generation. The company plans phased capability investment in bioconjugation, payload/linker, R&D, quality, safety and maintenance; a total quantified programme is not disclosed in Q2. On hypothetical ₹500 crore incremental productive investment, a 15% after-tax return needs ₹100 crore EBIT at 25% tax; with ₹25–40 crore depreciation, ₹125–140 crore EBITDA requires ₹500–560 crore sales at 25% margin. Not guidance. Track maintenance/compliance separately from growth and qualify actual assets before assuming return.
Key takeaways
Management acknowledged a fatal incident involving a colleague at Suryapet and a closure order, with corrective/preventive action begun and further impact under assessment. The human loss is serious independent of financial consequences. No assumption of reopening, independently established cause or quantified full exposure is made. Monitor official investigation and closure/restart orders, remedial actions, worker safety, customer continuity and any liabilities. Cost reduction must not compromise quality or safety. Management also reported US FDA inspections at Pashamylaram, Shamshabad and Jaggayyapeta, responses submitted and CAPA ongoing. Submission does not prove regulatory closure or a clean inspection. Verify official classifications and follow-up disclosures. Regulatory and safety spending may be necessary while profitability is depressed; do not treat compliance as a discretionary cost lever.
Key takeaways
FY26 derived operating EBITDA ₹426.99 crore gives 41.3x narrow EV/EBITDA. It is a directional metric, not fully comparable EV. Parent earnings are the clearer basis; model 38.5 crore shares, normal tax and explicit positive minority profit rather than capitalise tax refunds and subsidiary losses.
| FY28 assumption (₹cr except EPS/price) | Bear | Base | Bull |
|---|---|---|---|
| Operating revenue | 2400 | 3000 | 3600 |
| Operating EBITDA margin | 12% | 20% | 27% |
| Operating EBITDA | 288 | 600 | 972 |
| Other income | 25 | 25 | 25 |
| D&A | 200 | 220 | 240 |
| Finance cost | 40 | 35 | 35 |
| PBT | 73 | 370 | 722 |
| Group PAT at 25% tax | 54.75 | 277.50 | 541.50 |
| NCI profit | 5 | 10 | 20 |
| Parent PAT | 49.75 | 267.50 | 521.50 |
| EPS on 38.5cr shares | 1.29 | 6.95 | 13.55 |
| Terminal P/E assumption | 30x | 45x | 50x |
| Indicative price ₹ | 39 | 313 | 677 |
| Change vs reference | -91% | -32% | +48% |
Bear assumes weak utilisation and integration, base assumes revenue CAGR ~15% from FY26 and a 20% derived margin versus FY26 18.8%, bull ~26% CAGR, 27% margin and major commercial contribution. These are independent analyst cases, not company guidance, consensus or probability-weighted price targets.
Dividends and discounting excluded. Base parent PAT rises to ₹267.5 crore yet price is below reference; the starting multiple makes earnings recovery insufficient by itself. Bull requires both a stronger business and a premium valuation.
At base EPS ₹6.95, reference requires ~65.8x FY28 earnings merely to preserve price.
Reverse valuation at 45x: required EPS ₹10.17, parent PAT ₹391.5 crore on 38.5 crore shares. Add ₹10 crore NCI profit, group PAT ₹401.5 crore; at 25% tax PBT ₹535.3 crore. With base D&A ₹220 crore, finance ₹35 crore and other income ₹25 crore, operating EBITDA required ₹765.3 crore.
At 20% margin sales ₹3,826 crore, roughly 30% two-year CAGR from FY26. At 25% margin hurdle ₹3,061 crore, at 15% ₹5,102 crore. At EPS ₹5, 30x/40x/50x implies ₹150/200/250; ₹8 gives ₹240/320/400; ₹12 gives ₹360/480/600.
Each incremental ₹100 crore revenue at 25% margin and 25% tax adds ₹18.75 crore group PAT before extra depreciation/interest, ~₹0.49 EPS if all attributable, ₹21.9 at 45x. A full DCF needs subsidiary-specific economics, capex and working capital, tax and liabilities; cash released in H1 cannot be annualised as steady owner cash.
No unverified peer multiple or precise DCF is asserted.
Catalysts: Q3/Q4 small-molecule deliveries, positive H2 YoY revenue and EBITDA, ADC reloads, NJ Bio progress toward breakeven, recurring Sapala demand, API+ recovery and improving specialty orders. Require group pre-tax profit, reported margin, cash before temporary working-capital releases and verified safety/regulatory progress. Risks: commercial customer concentration, clinical failure and shipment deferral; continued ADC destocking; API cost inflation and agrochemical pricing/volume; acquisition integration and goodwill impairment; changing NCI; Suryapet closure/restart and inspection CAPA; inventory and tax-refund-dependent cash; capital ahead of demand; multiple compression.
These can occur together. WATCH until better earnings/cash or price improves the risk-reward. Do not use a sentiment score or a signed award alone as a purchase instruction.
Source ledger
S1. Cohance Q2/H1 statutory consolidated results and board outcome, 6 November 2026: . P&L, balance sheet, cash flows and notes 4–6 anchor figures, tax, NCI and acquisitions. Original table text accessible; screenshot retrieval failed.
S2. Issuer investor presentation, 6 November: . Canonical 76364, current semantic ACCEPT. Financial highlights, mix, adjusted EBITDA, cash/capex and H2 outlook.
S3. Call held 6 November, filed 11 November: https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_11112026175134_Cohance_Q2_FY27_concall_transcript.pdf . Canonical 88449, current semantic ACCEPT. Management discussion of reloads, awards, ADC destocking, Sapala, capacity, safety and inspection responses.
S4. Exchange board outcome and issuer release: https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_06112026174827_Cohance_Outcome_BM_06112026_uploading.pdf . S5. Sage PRO current quote ₹457.60, financial data, 16 November 2026; refresh before trading.
Key takeaways
Issuer Q2 statutory results / presentation / analyst calculation
Issuer Q2 statutory results / presentation / analyst calculation
Issuer Q2 statutory results / presentation / analyst calculation
Issuer Q2 statutory results / presentation / analyst calculation
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.